BG Medicine Announces Receipt of CE Mark for its Galectin-3 Blood Test
1/27/2010 11:38:52 AM
WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine, Inc., a privately-held developer of biomarker-based in vitro diagnostics, today announced the commercial launch in the European Union of a new, CE-marked test for the measurement of galectin-3 in human plasma or serum. Galectin-3 was first shown by researchers at the University of Maastricht, The Netherlands, to play an integral role in the development and progression of heart failure.
comments powered by